MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 28, 2006; DOI: 10.1124/mol.106.030866


0026-895X/07/7103-777-786$20.00
Mol Pharmacol 71:777-786, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.030866v1
71/3/777    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuneki, H.
Right arrow Articles by Sasaoka, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuneki, H.
Right arrow Articles by Sasaoka, T.

Novel G423S Mutation of Human {alpha}7 Nicotinic Receptor Promotes Agonist-Induced Desensitization by a Protein Kinase C-Dependent Mechanism

Hiroshi Tsuneki, Soushi Kobayashi, Kazue Takagi, Syota Kagawa, Masahiko Tsunoda, Masahiko Murata, Tadasu Matsuoka, Tsutomu Wada, Masayoshi Kurachi, Ikuko Kimura, and Toshiyasu Sasaoka

Departments of Clinical Pharmacology (H.T., S.K., K.T., S.K., T.W., I.K., T.S.) and Neuropsychiatry (M.T., T.M., M.K.), University of Toyama, Toyama, Japan; and Hokuriku National Hospital, Toyama, Japan (M.M.)

The {alpha}7 nicotinic acetylcholine receptor subunit (CHRNA7) gene harbors a high degree of polymorphism. In this study, we found a novel variant (1267 G to A) in exon 10 of the CHRNA7 gene in a Japanese population. This variant results in glycine-to-serine substitution at position 423 (G423S) located in the large cytoplasmic loop of the protein. To clarify the possibility that the G423S mutation alters the pharmacological properties of {alpha}7 receptors, acetylcholine (ACh)-elicited current through {alpha}7-G423S mutant receptors expressed in Xenopus laevis oocytes was measured using the two-electrode voltage-clamp technique. We found that the current elicited by ACh (1 mM, 5 s) through {alpha}7-G423S receptors, but not through {alpha}7 receptors, was significantly decreased by treatment with a protein kinase C activator, phorbol-12-myristate-13-acetate (PMA, 10–30 nM). In addition, PMA (10 nM) selectively promoted a progressive decrease in {alpha}7-G423S current induced by repetitive application of ACh pulses (1 mM, 0.1 s, 0.17–0.33 Hz) compared with {alpha}7 current. PMA also enhanced the inactivation of {alpha}7-G423S mutant receptors induced by a prolonged application of choline (30 µM) without affecting {alpha}7 receptor responses. Western blot analysis showed that the treatment with PMA (30 nM) increased the serine phosphorylation level of the {alpha}7-G423S mutant receptors but not that of the wild-type receptors. These findings demonstrate that the G423S mutation promotes receptor desensitization by a protein kinase C-dependent mechanism. Thus, we provide the first evidence that a variant in the human CHRNA7 gene alters the function of {alpha}7 nicotinic receptors.


Received September 13, 2006; accepted November 28, 2006

Address correspondence to: Dr. Hiroshi Tsuneki, Department of Clinical Pharmacology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. E-mail: htsuneki{at}pha.u-toyama.ac.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics